ADDF's Karen Harris: Investing in Alzheimer's Like a VC

How is venture philanthropy revolutionizing Alzheimer's drug discovery? We sit down with Karen Harris, CFO at the Alzheimer's Drug Discovery Foundation, to explore their game-changing approach to funding early-stage research. 
 
With $370M+ awarded to 765+ programs globally, the ADDF operates like a VC firm—using convertible debt and preferred equity to accelerate breakthrough treatments. 
 
Topics: 
Venture philanthropy vs traditional grants 
Shift from amyloid to combination therapies 
Blood-based biomarkers & precision medicine 
NIH funding cuts impact on research ecosystem 
 
Karen brings 20+ years investment banking experience to discuss how strategic capital is changing Alzheimer's research.